Tag:
MBX-2982
Latest Headlines
Latest Headlines
Sanofi terminates $375M Metabolex diabetes deal
Sanofi-Aventis has opted to terminate a deal with Metabolex that was worth up to $375 million in milestone payments. Less than a year ago Sanofi agreed to collaborate on MBX-2982, an orally active
Sanofi inks $375M deal with Metabolex for diabetes target
Hayward, CA-based Metabolex is on a roll, inking its second deal this week. The developer has secured an undisclosed upfront payment and up to $375 million from Sanofi-Aventis for rights to an
